Skip to content

Clinical Efficacy of Prolotherapy Combined with Perineural Injection in Patients with Knee Osteoarthritis

Clinical Efficacy of Prolotherapy Combined with Perineural Injection in Patients with Knee Osteoarthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062841
Enrollment
Unknown
Registered
2022-08-20
Start date
2022-08-20
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

one:ultrasound-guided suprapatellar bursal injection of Hypertonic glucose
two:injected 5% dextrose into the sensory nerves around the knee jointr under ultrasound guidance
three:Injecting hypertonic glucose into the knee joint while injecting 5% glucose around the sensory nerves around the knee joint

Sponsors

Li TieShan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the standards established by the ACR and EULAR (Meeting (1), and meeting any 2 of (2), (3), (4), and (5) at the same time, KOA can be diagnosed): (1) Repeatedly within the past month Knee joint pain; (2) X-ray (standing position or weight-bearing position) shows joint space narrowing, subchondral bone sclerosis and/or cystic degeneration, joint edge osteophyte formation; (3) Aged >= 48 years; (4) Morning Stiff time = 5; 4. Patients with poor curative effect after conservative treatment and strong willingness to injection treatment.

Exclusion criteria

Exclusion criteria: Exclusion criteria (satisfy one): 1. The diseased joints are combined with infection (including skin ulceration and infection around the injection site), joint tumors or tuberculosis; 2. Abnormal blood coagulation; 3. Severe cardiopulmonary disease and severe liver and kidney insufficiency; 4. No Cooperative treatment and follow-up patients with cognitive or mental disorders; 5. History of intra-articular drug injection and knee surgery within 3 months.

Design outcomes

Primary

MeasureTime frame
visual analogue scale;

Secondary

MeasureTime frame
The Western Ontario and McMaster Universities Arthritis Index;pressure pain threshold;

Countries

China

Contacts

Public ContactLI Tieshan

The Affiliated Hospital of Qingdao University

tieshanl@126.com+86 13964282582

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026